Skip to main content
Article thumbnail
Location of Repository

Loss of Tsc2 in radial glia models the brain pathology of tuberous sclerosis complex in the mouse

By Sharon W. Way, James McKenna, Ulrike Mietzsch, R. Michelle Reith, Henry Cheng-ju Wu and Michael J. Gambello


Tuberous sclerosis complex (TSC) is an autosomal dominant, tumor predisposition disorder characterized by significant neurodevelopmental brain lesions, such as tubers and subependymal nodules. The neuropathology of TSC is often associated with seizures and intellectual disability. To learn about the developmental perturbations that lead to these brain lesions, we created a mouse model that selectively deletes the Tsc2 gene from radial glial progenitor cells in the developing cerebral cortex and hippocampus. These Tsc2 mutant mice were severely runted, developed post-natal megalencephaly and died between 3 and 4 weeks of age. Analysis of brain pathology demonstrated cortical and hippocampal lamination defects, hippocampal heterotopias, enlarged dysplastic neurons and glia, abnormal myelination and an astrocytosis. These histologic abnormalities were accompanied by activation of the mTORC1 pathway as assessed by increased phosphorylated S6 in brain lysates and tissue sections. Developmental analysis demonstrated that loss of Tsc2 increased the subventricular Tbr2-positive basal cell progenitor pool at the expense of early born Tbr1-positive post-mitotic neurons. These results establish the novel concept that loss of function of Tsc2 in radial glial progenitors is one initiating event in the development of TSC brain lesions as well as underscore the importance of Tsc2 in the regulation of neural progenitor pools. Given the similarities between the mouse and the human TSC lesions, this model will be useful in further understanding TSC brain pathophysiology, testing potential therapies and identifying other genetic pathways that are altered in TSC

Topics: Articles
Publisher: Oxford University Press
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2001). A germ-line Tsc1 mutation causes tumor development and embryonic lethality that are similar, but not identical to, those caused by Tsc2 mutation in mice.
  2. (2002). A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells.
  3. (2005). A mouse model of tuberous sclerosis 1 showing background specific early post-natal mortality and metastatic renal cell carcinoma.
  4. (2007). A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival.
  5. (1997). A role for Cajal–Retzius cells and reelin in the development of hippocampal connections.
  6. (2004). Absence of allelic loss in cytomegalic neurons of cortical tuber in the Eker rat model of tuberous sclerosis.
  7. (2005). Astrocyte activation and reactive gliosis.
  8. (2002). Astrocyte-specific TSC1 conditional knockout mice exhibit abnormal neuronal organization and seizures.
  9. (1998). Autism and tuberous sclerosis.
  10. (2004). Behavioral and cognitive aspects of tuberous sclerosis complex.
  11. (2004). Brain abnormalities in tuberous sclerosis complex.
  12. (2007). Characteristics of abnormal diffusivity in normal-appearing white matter investigated with diffusion tensor MR imaging in tuberous sclerosis complex.
  13. (2004). Cortical neurons arise in symmetric and asymmetric division zones and migrate through specific phases.
  14. (2002). Dividing precursor cells of the embryonic cortical ventricular zone have morphological and molecular characteristics of radial glia.
  15. (2002). Doublecortin is required in mice for lamination of the hippocampus but not the neocortex.
  16. (2001). Drosophila Tsc1 functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size.
  17. (2005). Effects of rapamycin in the Eker rat model of tuberous sclerosis complex.
  18. (2005). Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models.
  19. (1996). Embryonic neuronal markers in tuberous sclerosis: single-cell molecular pathology.
  20. (2005). expressed sequentially by radial glia, intermediate progenitor cells, and postmitotic neurons in developing neocortex.
  21. (2004). Fibroblast growth factor receptor 1 is required for the proliferation of hippocampal progenitor cells and for hippocampal growth in mouse.
  22. (2003). GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR.
  23. (2007). Generation of a conditional disruption of the Tsc2 gene.
  24. (2007). Genotype/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States.
  25. (2007). Giant cells: contradiction to two-hit model of tuber formation?
  26. (1998). Graded reduction of Pafah1b1 (Lis1) activity results in neuronal migration defects and early embryonic lethality.
  27. (2005). Growing roles for the mTOR pathway.
  28. (2005). Hemimegalencephaly and tuberous sclerosis complex.
  29. (2002). Hemimegalencephaly in tuberous sclerosis complex.
  30. (2001). hGFAP-cre transgenic mice for manipulation of glial and neuronal function in vivo.
  31. (1993). Identification and characterization of the tuberous sclerosis gene on chromosome 16.
  32. (2002). Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway.
  33. (1997). Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34.
  34. (2003). Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2.
  35. (2004). Managing epilepsy in tuberous sclerosis complex.
  36. (2000). Molecular genetic advances in tuberous sclerosis.
  37. (2006). Molecular genetic determinants of human brain size.
  38. (2007). Molecular mechanisms of astrogliosis: new approaches with mouse genetics.
  39. (2004). Molecular pathogenesis of tuber formation in tuberous sclerosis complex.
  40. (2004). Mouse models of tuberous sclerosis complex.
  41. (2002). mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery.
  42. (2001). Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates 1264 Human Molecular Genetics,
  43. (2007). Neocortical hyperexcitability in a human case of tuberous sclerosis complex and mice lacking neuronal expression of TSC1.
  44. (2003). Neuronal or glial progeny: regional differences in radial glia fate.
  45. (2004). Neurons arise in the basal neuroepithelium of the early mammalian telencephalon: a major site of neurogenesis.
  46. (2001). Neurons derived from radial glial cells establish radial units in neocortex.
  47. (2008). Oligodendrocyte differentiation and implantation: new insights for remyelinating cell therapy.
  48. (2004). Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.
  49. (2002). Radial glia: multi-purpose cells for vertebrate brain development.
  50. (2007). Radial glial cell heterogeneity—the source of diverse progeny in the CNS.
  51. (2006). Rapamycin causes regression of astrocytomas in tuberous sclerosis complex.
  52. (2008). Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.
  53. (2007). Recent developments in neurofibromatosis type 1.
  54. (1998). Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase 9.
  55. (2002). Regulation of cerebral cortical size by control of cell cycle exit in neural precursors.
  56. (1999). Renal carcinogenesis, hepatic hemangiomatosis, and embryonic lethality caused by a germ-line Tsc2 mutation in mice.
  57. (2008). Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function.
  58. (2003). Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins.
  59. (2007). Sirolimus (rapamycin): from the soil of Easter Island to a bright future.
  60. (2008). Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.
  61. (2005). Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations.
  62. (2004). subventricular zone and upper layers II–IV of the cerebral cortex.
  63. (2008). Tbr2 directs conversion of radial glia into basal precursors and guides neuronal amplification by indirect neurogenesis in the developing cortex.
  64. (2001). The Drosophila tuberous sclerosis complex gene homologs restrict cell growth and cell proliferation.
  65. (2006). The tuberous sclerosis complex.
  66. (2000). The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination.
  67. (2002). Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling.
  68. (2001). TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth.
  69. (1999). Tsc2(þ/2) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background.
  70. (1995). Tuber and subependymal giant cell astrocytoma associated with tuberous sclerosis: an immunohistochemical, ultrastructural, and immunoelectron and microscopic study.
  71. (1999). Tuberous Sclerosis Complex, 3rd edn.
  72. (1997). Tuberous sclerosis in a 20-week gestation fetus: immunohistochemical study.
  73. (2008). Tuberous sclerosis: a primary pathology of astrocytes?
  74. (1998). White matter abnormalities in tuberous sclerosis complex.
  75. (2007). Wrapping it up: the cell biology of myelination.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.